Table 2 Clinical characteristics of patients with HER2-low vs HER2-0 expression
From: Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
HER2-0 | HER2-low | P value | |
|---|---|---|---|
Age | 0.021 | ||
≥ 60y | 39 | 35 | |
< 60y | 40 | 15 | |
Sex | 0.154 | ||
Male | 56 | 41 | |
Female | 23 | 9 | |
Tumor location | 0.032 | ||
Cardia | 13 | 11 | |
Corpus | 20 | 29 | |
Antrum | 17 | 39 | |
Differentiation | 0.027 | ||
Poor | 59 | 28 | |
Well | 20 | 22 | |
Tumor invasion | 0.304 | ||
T1 | 11 | 3 | |
T2 | 12 | 8 | |
T3 | 36 | 20 | |
T4 | 20 | 19 | |
Lymph node | 0.668 | ||
N0 | 20 | 11 | |
N + | 59 | 39 | |
TNM stage | 0.15 | ||
I | 18 | 5 | |
II | 17 | 15 | |
III | 44 | 30 | |
Ki-67 index | 0.021 | ||
Low | 40 | 15 | |
High | 39 | 35 |